This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Review paper

Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

Volume: 14, Issue: 2, Pages: 61 - 71
Published: Jan 24, 2019
Abstract
The landscape of HCV treatment has been entirely transformed due to the development of direct-acting antivirals (DAAs), but there are limited data guiding salvage therapy in patients who previously failed an NS5A inhibitor-containing DAA regimen. We review the preclinical and clinical data for sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pan-genotypic treatment for chronic HCV infection. This...
Paper Details
Title
Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
Published Date
Jan 24, 2019
Volume
14
Issue
2
Pages
61 - 71
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.